{
    "clinical_study": {
        "@rank": "43580", 
        "arm_group": [
            {
                "arm_group_label": "Group 1: CYD dengue vaccine", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive a dose on CYD dengue vaccine at Day 0, and month 2 and 6, respectively"
            }, 
            {
                "arm_group_label": "Group 2: CYD dengue vaccine", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive a dose on CYD dengue vaccine at Day 0, and month 6 and 12, respectively"
            }, 
            {
                "arm_group_label": "Group 3: CYD dengue and IXIARO vaccines", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive a dose on CYD dengue and IXIARO (JE) vaccines at Day 0, JE at month 1, and CYD dengue at month 2 and 6 and 12, respectively"
            }, 
            {
                "arm_group_label": "Group 4: IXIARO (JE) vaccine", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive a dose of IXIARO (JE) vaccines at Day 0 and at month 1; and CYD dengue at months 7, 9 and 13, respectively"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to evaluate a compressed dosing schedule and the immunologic effects\n      of co-administration of a flavivirus with JE vaccine.\n\n      Primary Objectives:\n\n        -  To describe and compare the humoral immune response to each of the 4 parental dengue\n           virus serotypes at baseline and 28 days after each CYD dengue vaccine dose.\n\n        -  To describe the persistence of the humoral immune response to each of the 4 parental\n           dengue virus serotypes 6 months after CYD dengue vaccine Dose 3, irrespective of\n           whether or not JE vaccine has been previously administered.\n\n      Secondary Objectives:\n\n        -  To describe the safety profile after each injection of CYD dengue vaccine.\n\n        -  To describe the humoral immune response to each of the 4 parental dengue virus\n           serotypes at baseline and 28 days after each CYD dengue vaccine dose when administered\n           with or after JE virus vaccine.\n\n        -  To describe the persistence of the humoral immune response to each of the 4 parental\n           dengue virus serotypes at six months post-Dose 3 in all four groups and at 12 months\n           post dose 3 in Groups 1 and 3 with the compressed schedule.\n\n        -  To describe the JE humoral immune response 28 days after each injection of CYD dengue\n           vaccine."
        }, 
        "brief_title": "Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Dengue", 
            "Dengue Fever", 
            "Dengue Hemorrhagic Fever"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dengue", 
                "Dengue Hemorrhagic Fever", 
                "Fever", 
                "Hemorrhagic Fevers, Viral"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study participants will be randomly assigned to one of the four groups to receive assigned\n      study vaccine and will be evaluated neutralizing antibody (Ab) titers; markers of\n      cell-mediated immunity (CMI)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged \u2265 18 to \u2264 45 years on the day of inclusion\n\n          -  Informed consent form has been signed and dated\n\n          -  Able to attend all scheduled visits and to comply with all trial procedures\n\n          -  Subject in good health, based on medical history and physical examination.\n\n        Exclusion Criteria:\n\n          -  Subject is pregnant, or lactating, or of childbearing potential (to be considered of\n             non-childbearing potential, a female must be post- menopausal for at least 1 year,\n             surgically sterile, or using an effective method of contraception or abstinence from\n             at least 4 weeks prior to the first vaccination and until at least 4 weeks after the\n             last vaccination)\n\n          -  Participation in the 4 weeks preceding the first trial vaccination, or planned\n             participation during the present trial period, in another clinical trial\n             investigating a vaccine, drug, medical device, or medical procedure\n\n          -  Receipt or planned receipt of any vaccine, outside the study protocol in the 4 weeks\n             preceding or following trial vaccinations. (If influenza activity warrants\n             vaccination of healthy young adults, influenza vaccination will be encouraged and\n             will not lead to study exclusion.)\n\n          -  Any history of  flavivirus (FV) vaccination, or planned FV vaccination during the\n             trial period.\n\n          -  Previous residence (>12 months) in, or travel in the last 30 days to dengue endemic\n             regions.\n\n          -  Receipt of immune globulins, blood or blood-derived products in the 3 months prior to\n             first vaccination or planned use during the study period\n\n          -  Known or suspected congenital or acquired immunodeficiency; or receipt of\n             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy\n             within the preceding 6 months; or long-term systemic corticosteroid therapy\n             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n\n          -  Known systemic hypersensitivity to any of the vaccine components (including protamine\n             sulfate), or history of a life-threatening reaction to the vaccine(s) used in the\n             trial or to a vaccine containing any of the same substances, including dry natural\n             latex\n\n          -  Deprived of freedom by an administrative or court order, or in an emergency setting,\n             or hospitalized involuntarily\n\n          -  Excessive alcohol consumption or drug addiction\n\n          -  Chronic illness that, in the opinion of the Investigator, is at a stage where it\n             might interfere with trial conduct or completion\n\n          -  Identified as an employee of the Investigator or study center, with direct\n             involvement in the proposed study or other studies under the direction of that\n             Investigator or study center, as well as family members (i.e., immediate, husband,\n             wife and their children, adopted or natural) of the employee or the Investigator\n\n          -  Temporary Exclusion Criteria: Moderate or severe acute illness/infection (according\n             to Investigator judgment) on the day of vaccination or febrile illness (temperature \u2265\n             38.0\u00b0C [\u2265 100.4\u00b0F]). A prospective subject should not be included in the study until\n             the condition has resolved or the febrile event has subsided.  If the delay for the\n             febrile illness exceeds the window between screening and vaccination, or if deemed\n             necessary by the Investigator, a prospective subject may be re-screened once the\n             fever has resolved."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01943825", 
            "org_study_id": "CYD56", 
            "secondary_id": "U1111-1143-8391"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1: CYD dengue vaccine", 
                "description": "0.5 mL, Subcutaneous", 
                "intervention_name": "CYD Dengue Vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group 2: CYD dengue vaccine", 
                "description": "0.5 mL, Subcutaneous", 
                "intervention_name": "CYD Dengue Vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group 3: CYD dengue and IXIARO vaccines", 
                "description": "0.5 mL, Subcutaneous (CYD) Intramuscular (JE)", 
                "intervention_name": "CYD Dengue and Japanese Encephalitis Vaccines", 
                "intervention_type": "Biological", 
                "other_name": "IXIARO Japanese Encephalitis Vaccine"
            }, 
            {
                "arm_group_label": "Group 4: IXIARO (JE) vaccine", 
                "description": "0.5 mL, Intramuscular (JE), Subcutaneous (CYD)", 
                "intervention_name": "Japanese Encephalitis and CYD Dengue Vaccines", 
                "intervention_type": "Biological", 
                "other_name": "IXIARO Japanese Encephalitis Vaccine"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Dengue", 
            "Dengue fever", 
            "CYD dengue vaccine", 
            "IXIARO JE vaccine", 
            "Flavivirus"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "link": [
            {
                "url": "http://www.sanofipasteur.com"
            }, 
            {
                "url": "http://www.sanofi.com"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Syracuse", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "13210"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine", 
        "overall_contact": {
            "email": "RegistryContactUs@sanofipasteur.com", 
            "last_name": "Public Registry Sanofi Pasteur"
        }, 
        "overall_official": {
            "affiliation": "Sanofi Pasteur SA", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Neutralizing antibody levels by microneutralization assay and/or plaque reduction neutralization test (PRNT) against each of the 4 parental dengue virus serotypes at baseline and 28 days after each CYD dengue vaccine dose in all four groups", 
                "safety_issue": "No", 
                "time_frame": "28 days post CYD dengue vaccination"
            }, 
            {
                "measure": "Neutralizing antibody levels by microneutralization assay and/or PRNT against each of the 4 parental dengue virus serotypes 6 and/or 12 months after CYD dengue vaccine Dose 3 in all four groups", 
                "safety_issue": "No", 
                "time_frame": "6 and 12 months post CYD dengue vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01943825"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Description of the Safety profile in terms of solicited injection site and systemic reaction, unsolicited adverse events and serious adverse events after each vaccination with CYD dengue and/or JE vaccines", 
                "safety_issue": "No", 
                "time_frame": "Day 0 up to 6 months post last vaccination"
            }, 
            {
                "measure": "Neutralizing antibody levels, measured by microneutralization assay and/or PRNT, against each of the four parental dengue virus serotypes at baseline and 28 days after each CYD dengue vaccine dose in Groups 3 and 4.", 
                "safety_issue": "No", 
                "time_frame": "28 days post CYD dengue vaccination"
            }, 
            {
                "measure": "Neutralizing antibody levels, measured by microneutralization assay and/or PRNT, against each of the four parental dengue virus serotypes at 6 months post Dose 3 in all subjects and at 12 months post Dose 3 in Groups 1 and 3", 
                "safety_issue": "No", 
                "time_frame": "6 and 12 months post dose 3 CYD dengue vaccination"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Department of Defense", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi Pasteur, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}